Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, placebo-controlled study of two doses of oral 6R-BH4 [sapropterin] on vascular function in subjects with coronary artery disease

Next Previous
Trial Profile

A randomised, placebo-controlled study of two doses of oral 6R-BH4 [sapropterin] on vascular function in subjects with coronary artery disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sapropterin (Primary)
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms OXBIO

Most Recent Events

  • 26 Jul 2020 Status changed from recruiting to completed.
  • 01 Sep 2010 Results presented at the ESC Congress 2010: Annual Congress of the European Society of Cardiology.
  • 06 Aug 2008 The expected completion date (Feb 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top